Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06580938 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT06580938 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 4 participants.
The verdict
NCT06580938, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07921585) in people with cancer that has advanced or spread to other parts of the body. This study is seeking participants who have any of the following cancer types: * non-small cell lung cancer * colorectal cancer * bladder cancer * melanoma (a type of skin cancer) * kidney cancer * head and neck cancer Participants will receive the study medicine PF-07921585 alone or in combination with another study medicine called sasanlimab at the study clinic. PF-07921585 will be given as an infusion into a vein or as shots under the skin, once every 3 weeks. Sasanlimab will be given as shots under the skin, also once every 3 weeks. The experiences of participants receiving the study medicine will be studied to help see if the study medicine is safe and effective. Participants may receive study medicine for up to 2 years, depending on how the cancer responds to the study treatment. Participants may continue receiving study medicine after 2 years if there are any benefits from the study treatment. Participants will attend visits once every 3 weeks with the first 9 weeks having more frequent visits, to check the safety of the study treatment.
Interventions
- BIOLOGICAL Sasanlimab
- BIOLOGICAL PF-07921585
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-11-11 |
| Est. Completion | 2025-07-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06580938
The ClinicalTrials.gov registry entry for NCT06580938 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sasanlimab is the first listed.
NCT06580938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06580938 about?
NCT06580938 is a clinical study titled "A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer". The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07921585) in people with cancer that has advanced or spread to other parts of the body. This study is seeking participants who have any of the following cancer types: * non-small cell lung cancer * ...
What is the current status of trial NCT06580938?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2024-11-11. Estimated completion is 2025-07-14.
What interventions are being tested in trial NCT06580938?
The interventions under investigation include: Sasanlimab (BIOLOGICAL), PF-07921585 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06580938?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.